The use of Janus Kinase inhibitors in hospitalized patients with COVID-19: Systematic review and meta-analysis
Background: The evidence of using JAK inhibitors among hospitalized patients with COVID-19 is conflicting. The systematic review and meta-analysis aimed to address the efficacy of Janus Kinase (JAK) Inhibitors in reducing risk of mortality among hospitalized patients with COVID-19. Methods: Several...
Main Authors: | Indra Wijaya, Rizky Andhika, Ian Huang, Aga Purwiga, Kevin Yonatan Budiman, Muhammad Hasan Bashari, Lelani Reniarti, Rully Marsis Amirullah Roesli |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-07-01
|
Series: | Clinical Epidemiology and Global Health |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2213398421000592 |
Similar Items
-
Janus Kinases in Leukemia
by: Juuli Raivola, et al.
Published: (2021-02-01) -
Janus Associated Kinases Inhibitors in the Pharmacological Thera
by: Daniela Santos1, et al.
Published: (2017-01-01) -
Basics of Janus kinases: a review
by: Hanan R Nada, et al.
Published: (2020-01-01) -
Targeting the Janus Kinase Family in Autoimmune Skin Diseases
by: Michael D. Howell, et al.
Published: (2019-10-01) -
Immunohistochemistry of Janus Kinase 1 (JAK1) Expression in Vitiligo
by: Asmaa Gaber Abdou, et al.
Published: (2018-11-01)